Non-opioid Pain Target healthcare providers treating chronic post-amputation pain with non-opioid solutions. Neuros Medical offers the Altius Direct Electrical Nerve Stimulation System, a FDA-approved alternative that addresses phantom and residual limb pain, presenting an opportunity to expand into pain management clinics and prosthetics centers seeking opioid-sparing therapies.

Expansion Readiness Leverage Neuros’ Series D funding and strong growth trajectory to position larger medical device distributors and hospital networks as partners for broader adoption. The recent $56M financing signals scalability, potential for accelerated market penetration, and willingness to expand commercialization and support services.

Key Leadership Engage with newly appointed CEO David Veino and executive leadership who led pivotal trials. Target high-level conversations around clinical outcomes, payer strategies, and path-to-market for new centers of excellence in post-amputation pain management.

Clinical Validation Align sales efforts with the completed QUEST pivotal trial and FDA-approved status to build credibility. Focus on institutions seeking evidence-based non-opioid therapies, post-amputation pain management programs, and integration with rehabilitation and prosthetics services.

Strategic Partnerships Explore collaborations with large medical technology players and specialty distributors who serve orthopedic, neuromodulation, and pain management markets. Complementary partnerships can accelerate adoption in hospital systems, outpatient clinics, and durable medical equipment channels.